Jonathan Hill, PhD

Entrepreneur-In-Residence

Jonathan Hill is an Entrepreneur-in-Residence at Raven. Jonathan’s primary responsibility is to evaluate and incubate early-stage therapeutic programs. Prior to Raven, Jonathan most recently served as Vice President of Biology at Surface Oncology, where he led a diverse group of scientists in developing therapeutic antibodies to enhance anti-tumor immune responses in patients with cancer. His team’s responsibilities spanned from target validation to IND-enabling studies and supported translational efforts to monitor these therapeutics’ biological activity in clinical trials. Prior to Surface Oncology, Jonathan held several positions of increasing responsibility at Tempero Pharmaceuticals and GlaxoSmithKline within the Immuno-Inflammation Therapeutic Area. His group’s efforts were focused on target identification/​validation and high-throughput phenotypic screening aimed at modulating Treg and Th17 cells in autoimmune disease and cancer. Jonathan holds a BS in Biochemistry and PhD in Immunology at the University of Western Ontario and was a post-doctoral fellow in the lab of Christophe Benoist and Diane Mathis at Harvard Medical School.